Sio Gene Therapies IncNASDAQ:SIOXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4401
- TODAY'S CHANGE (%)0.0001 (0.0227%)
- Bid / Lots0.4400/ 21
- Ask / Lots0.4430/ 2
- Open / Previous Close0.4400 / 0.4400
- Day Range
- 52 Week Range
- Volume57,658
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SIOX |
|---|---|---|
| 09:32 ET | 1489 | 0.44 |
| 09:33 ET | 2416 | 0.4431 |
| 09:48 ET | 49913 | 0.4398 |
| 09:50 ET | 100 | 0.44 |
| 10:04 ET | 100 | 0.4448 |
| 10:08 ET | 1200 | 0.44 |
| 10:11 ET | 200 | 0.4401 |
| 10:18 ET | 100 | 0.4447 |
| 10:22 ET | 359 | 0.4446 |
| 10:38 ET | 1000 | 0.4401 |
| 10:51 ET | 300 | 0.4401 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sio Gene Therapies Inc | 32.5M | -0.6x | --- |
Coeptis Therapeutics Holdings Inc | 32.3M | 15.6x | --- |
Equillium Inc | 34.3M | -0.4x | --- |
Cadrenal Therapeutics Inc | 29.9M | 0.0x | --- |
Moleculin Biotech Inc | 36.1M | -1.4x | --- |
Shuttle Pharmaceuticals Inc | 28.1M | 0.0x | --- |
Company Information
Sio Gene Therapies Inc. is a clinical-stage company. The Company is focused on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. The Company is primarily focused on pre-clinical research and development initiatives in gene therapy.
Contact Information
- Headquarters
- 1501 Broadway, 12Th FloorNEW YORK, NY, United States 10036
- Phone
- 302-636-5400
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Frank Torti
- Chief Executive Officer, Director
- Pavan Cheruvu
- Chief Financial Officer, Chief Accounting Officer, General Counsel
- David Nassif
- Chief Research and Development Officer
- Gavin Corcoran
- Lead Independent Director
- Atul Pande
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 74.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.68 |
Book Value | $0.82 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
